Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ summarizes the results of two Phase III trials of daratumumab in multiple myeloma (MM) reported at ASCO and EHA. The CASTOR study (NCT02136134) reported at ASCO 2016 looks at the combination of daratumumab with bortezomib and dexamethasone vs bortezomib and dexamethasone. The results show that the addition of daratumumab to bortezimib in relapsed patients, improves reponse rate and progression-free survival (PFS). The POLLUX trial (NCT02076009) looking at daratumumab with lenalidomide and dexamethasone vs lenalidomide and dexamethasone reported at EHA 2016, also show improved response and PFS.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.